DaVita recognized as one of FORTUNE Magazine’s Most Admired Companies in 2010

DaVita Inc. (NYSE: DVA), a leading provider of kidney care services for those diagnosed with chronic kidney disease (CKD), has been recognized as one of FORTUNE Magazine’s Most Admired Companies in 2010 for the fifth consecutive year. This year, DaVita® ranked first among Health Care Medical Facilities overall, and was specifically recognized in the magazine’s categories of Innovation, Use of Corporate Assets, Financial Soundness, Long-Term Investment and Quality of Products and Services.

“Ranking first overall in Health Care Medical Facilities is wonderful recognition for the hard work that our nephrologist partners and 34,000 teammates do every day and a testament to their dedication to improving the lives of people with kidney disease.”

“DaVita is committed not only to delivering high-quality care to our more than 118,000 patients, but to shaping the future of health care through clinical innovation and corporate stewardship,” said Kent Thiry, Chairman and Chief Executive Officer of DaVita. “Ranking first overall in Health Care Medical Facilities is wonderful recognition for the hard work that our nephrologist partners and 34,000 teammates do every day and a testament to their dedication to improving the lives of people with kidney disease.”

A total of 667 companies from 33 countries across 55 industries were surveyed to create the lists. Approximately 15,000 senior executives, outside directors and industry analysts were asked to rate companies in their own industries on nine criteria, such as investment value and social responsibility. To meet FORTUNE’s high standard for recognition, a company's score must rank in the top half of its industry.

DaVita is a registered trademark of DaVita Inc. All other trademarks are the property of their respective owners.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Statins found to prevent chronic inflammation-related cancers by inhibiting interleukin-33